Latest News
2011-11-15
CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project co-funded by the U.S. Defense Advanced Research Projects AgencyCureVac gibt Zusammenarbeit mit Sanofi Pasteur im Rahmen eines 33,1 Mio. Dollar Projektes bekannt
2011-11-07
CureVac presents results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA based cancer vaccine, at the 26th Annual SITC Meeting in WashingtonCureVac präsentiert vielversprechende Ergebnisse einer Phase I / IIa-Studie mit dem mRNA-basierten Krebsimpfstoff CV9201 an Patienten mit nicht-klein- zelligem Lungenkrebs (NSCLC)
2011-10-06
CureVac presents promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO ConferenceCureVac präsentiert neue vielversprechende Daten für Prostatakrebsimpfstoff CV9103 und Lungenkrebsimpfstoff CV9201 auf der Onkologie-Konferenz ASCO
Contact
Give us a call or send an email for further information:
T +49(0)7071.92053-61
T +49(0)7071.92053-61
Get in touch with CureVac
If you are interested in partnering with us, or working for us, we would be pleased to talk to you.
You are welcome to contact us direct or meet us at events where CureVac people are attending or presenting papers.
Please contact us in advance if you wish to make a specific appointment at any of the following:
January 9 - 12, 2012
30th Annual J.P. Morgan Healthcare ConferenceSan Francisco, USA
March 19 - 21, 2012
BIO-Europe Spring 2012Amsterdam, Netherlands
March 31 - April 4, 2012
AACR Annual Meeting 2012Chicago, USA
May 23 - 25, 2012
CIMT Annual Meeting 2012Mainz,Germany